Axsome Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Axsome Therapeutics, Inc. on June 5, 2026. The report details the adoption of a new executive compensation plan effective as of the filing date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and executive compensation arrangements rather than financial performance.
Material Changes
The primary material change is the adoption of the "Axsome Therapeutics, Inc. Executive Severance and Change in Control Plan" (Severance Plan). This new plan supersedes all prior severance plans, agreements, and arrangements for key employees, including named executive officers.
Plan Details and Management Commentary
The Compensation Committee approved the Severance Plan to provide benefits upon qualifying termination events. The plan categorizes participants into three tiers:
- Tier 1: Includes the Chief Executive Officer.
- Tier 2: Includes all other Section 16 executive officers.
- Tier 3: Includes vice presidents and above.
Severance Benefits (Outside Change in Control):
- Tier 1: 18 months of base salary and 18 months of COBRA premiums.
- Tier 2: 12 months of base salary and 12 months of COBRA premiums.
- Tier 3: 6 months of base salary and 6 months of COBRA premiums.
Enhanced Severance Benefits (During Change in Control Period):
- Tier 1: 24 months of base salary, pro-rated target annual incentive, 100% equity vesting (time and performance), and 24 months of COBRA premium differential.
- Tier 2: 18 months of base salary, pro-rated target annual incentive, 100% equity vesting, and 18 months of COBRA premium differential.
- Tier 3: 9 months of base salary, pro-rated target annual incentive, 100% equity vesting, and 9 months of COBRA premium differential.
Investor Verification Checklist
- Review the full text of the Executive Severance and Change in Control Plan filed as Exhibit 10.1.
- Verify the specific definitions of "Involuntary Termination" and "Good Reason" within the plan.
- Confirm the list of employees designated as Tier 1, Tier 2, and Tier 3 participants.
- Assess the potential financial impact of the enhanced equity vesting provisions in the event of a Change in Control.